6 days Ago By Defense World Staff
LPL Financial LLC cut its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The fund owned 49,882 shares of the company’s stock after selling 6,462 shares during the quarter. LPL Financial LLC owned about 0.08% of Twist Bioscience worth $2,318,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the business. Barclays PLC raised its holdings in Twist Bioscience by 214.8% in the 3rd quarter.
Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Twist Bioscience in the fourth quarter valued at $1,059,000. Principal Financial Group Inc.
lifted its position in Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc.
now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares during the period. Oddo BHF Asset Management Sas acquired a new stake in Twist Bioscience during the third quarter worth $3,302,000. Finally, KBC Group NV increased its holdings in Twist Bioscience by 71.
4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the period. Insider Transactions at Twist BioscienceIn other news, COO Patrick John Finn sold 2,422 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd.
The shares were sold at an average price of $50.17, for a total transaction of $121,511.74.
Following the completion of the sale, the chief operating officer now owns 272,044 shares of the company’s stock, valued at $13,648,447.48. This trade represents a 0.
88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction on Friday, February 7th.
The shares were sold at an average price of $53.13, for a total transaction of $156,202.20.
Following the transaction, the director now owns 18,173 shares in the company, valued at $965,531.49. The trade was a 13.
93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,796 shares of company stock worth $1,077,383.
Company insiders own 3.01% of the company’s stock. Twist Bioscience Stock Up 2.
5 %Shares of TWST opened at $39.82 on Tuesday. The company has a current ratio of 4.
96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.
Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.
90. The firm’s 50 day moving average is $41.55 and its 200-day moving average is $44.
60. The stock has a market capitalization of $2.38 billion, a PE ratio of -11.
78 and a beta of 2.34. Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings data on Monday, February 3rd.
The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.
09. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.
96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.
69%. The company’s revenue was up 24.1% on a year-over-year basis.
During the same period in the previous year, the business earned ($0.75) earnings per share. Equities research analysts forecast that Twist Bioscience Co.
will post -2.12 EPS for the current year. Wall Street Analysts Forecast GrowthA number of equities analysts have recently issued reports on TWST shares.
Robert W. Baird increased their target price on Twist Bioscience from $48.00 to $54.
00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their price objective on Twist Bioscience from $58.
00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Guggenheim set a $50.
00 target price on shares of Twist Bioscience in a report on Friday, March 28th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.
00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock.
According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.80.
Get Our Latest Stock Analysis on TWSTTwist Bioscience Profile (Free Report)Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.Featured StoriesFive stocks we like better than Twist BioscienceBest Stocks Under $10.
00 Why NVIDIA Stock Could Soar Despite Wall Street DowngradesWhat Investors Need to Know About Upcoming IPOsTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldMost Volatile Stocks, What Investors Need to Know3 Hot New IPOs Defying the 2025 Market Slump.
